viernes, 30 de mayo de 2014

WHO Pharmaceuticals Newsletter (No.2, 2014)



OMS, 30 de mayo 2014

Regulatory Matters

Aliskiren, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers ........................................................................................ ….............................4
Azathioprine and mercaptopurine .................................. ............................... 4
Cetuximab ..................................................................... ................................ 4
Combined hormonal contraceptives ................ ........... ................................ .5
Diacerein-containing medicines .......................... .. ....................................... 5
Doripenem ........................................................... ..........................................5
Lithium ..................................................................... .................................. ...5
Methysergide-containing medicines ........................... ................................... 6
Orlistat .......................................................................................................... 6
Quetiapine ................................................................... ................................. .7
Strontium ranelate ...........................................................................................7

Safety of medicines
Saxagliptin ...................................................................... ..............................8
St John’s wort and hormonal contraceptives, including implants .. ...............8
Testosterone Products ....................................................................................8

Signal
Combined Citalopram and Ramipril treatment - Hyponatraemia ...... ............ 10
Combined Ibuprofen and Metamizole treatment - Acute renal failure .......... 13
Tocilizumab – Psoriasis and Aggravated psoriasis ........................................ 16
Vemurafenib and Pancreatitis ........................................................................ 23


dsiponible en